PaySign, the Technology sector company, was revisited by a Wall Street analyst today. Analyst Gary Prestopino from Barrington maintained a Buy rating on the stock and has a $8.50 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gary Prestopino has given his Buy rating due to a combination of factors including PaySign’s impressive financial performance and strategic growth initiatives. The company reported a significant increase in revenue by 33.1% to $19.1 million and a remarkable 101.8% rise in adjusted EBITDA to $4.51 million for Q2/25, surpassing both internal and consensus expectations. This growth was driven by the robust performance of the Pharma Patient Affordability segment, which saw a 190% increase in revenue, highlighting the company’s ability to capitalize on high-growth opportunities.
Furthermore, PaySign’s strategic expansion, including the addition of 123 new plasma donation centers and seven new Pharma Patient Affordability programs, positions it well for future growth. The company’s proprietary dynamic business rules technology enhances its competitive edge by effectively addressing market challenges, thereby attracting new clients and expanding existing programs. These factors, combined with an improved gross profit margin and a strong pipeline for further growth, underpin Prestopino’s positive outlook on PaySign’s stock.
According to TipRanks, Prestopino is a 5-star analyst with an average return of 10.0% and a 52.34% success rate. Prestopino covers the Consumer Cyclical sector, focusing on stocks such as OPENLANE, Liquidity Services, and Commercial Vehicle Group.
In another report released on August 7, D.A. Davidson also maintained a Buy rating on the stock with a $9.00 price target.